CROCETIN: Novel Therapeutic and Preventive Approaches on Pancreatic Cancer

University of Kansas
posted on 08/21/2009

• request more info 
•   
•  LICENSE ONLINE

Description: Pancreatic cancer is most lethal malignancies in humans. Crocetin, an important constituent of saffron, has been emerged as carotenoids by chemical analysis of saffron extracts which showed significant potential as an antitumor effect associated with saffron treatment in animal models and cell culture systems. Researchers at University of Kansas Medical Center have been evaluating the molecular mechanisms responsible for antitumor effects of Crocetin. This invention is a novel drug therapy using crocetin in pancreatic cancer which will improve survival rates. Studies have been carried out on pancreatic cancer cell lines and mouse xenograft models. For more details on this patent pending technology please refer to the following publication. Dhar A, Mehta S, Dhar G, Dhar K, Banerjee S, Van Veldhuizen P, Campbell DR, Banerjee SK. Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model. Mol Cancer Ther. 2009 Feb;8(2):315-23. Epub 2009 Feb 10 Applications: Cancer Therapeutics Patent: Pending Confidential Disclosure Agreement (CDA): KU is willing to enter into a CDA for the purpose of negotiating a License Agreement. If you are interested in learning details of this invention, please contact: Aswini K. Betha, Ph.D. (abetha@ku.edu Ph: 913-588-5713)